Charcot-Marie-Tooth disease (CMT) is characterised by progressive motor and sensory neuropathy, resulting in muscle weakness and mobility impairments. The most common axonal form of CMT, CMT2A, is caused by mutations in the Mitofusin 2 (Mfn2) protein, which is a large GTPase critical for optimal mitochondrial functioning. Despite mutations of Mfn2 first being described as causative for CMT2A more than a decade ago, we still lack a precise understanding of how Mfn2 mutations cause the disease, and thus have a complete lack of effective therapeutics. We aim to model CMT2A in C. elegans by targeting the ortholog of Mfn2 in this species (
fzo-1) in order to better understand the disease pathophysiology and to discover novel drugs that can modulate the disease. Using CRISPR-Cas9 methods, we have generated a novel allele of
fzo-1 with the entire genomic region deleted (
cjn020). We have used this allele, as well as the
fzo-1(
tm1133) allele, to assess the consequences of
fzo-1 loss-of-function on animal behaviour, with a focus on locomotion and pharyngeal pumping. Notably, the absence of FZO-1 resulted in a significant reduction in the rate of locomotion compared to wild-type (WT) across all age groups tested, as demonstrated in both thrash and body bending assays. These observations mirror the mobility impairments endured by CMT2A patients. Furthermore, the two
fzo-1 mutant strains displayed progressive defects in pharyngeal pumping compared to WT, with irregular and slower pumping rates observed. As the rate of pharyngeal pumping depends on the cycle of contraction and relaxation of the pharyngeal muscles, which in turn is determined by the pharyngeal muscle action potential, a deficit in pharyngeal pumping rate implies a corresponding defect in the neuronal control of the pharyngeal muscle contraction/relaxation. Finally, we have exploited the locomotor dysfunction of
fzo-1 mutants as a platform for high-throughput screening of small compounds, in order to discover novel modulators that can reverse the movement defects in
fzo-1 mutant animals. Our results help to define the normal biological role of Mfn-2/FZO-1, how this relates to CMT2A, and will also identify effective modulators of the disease phenotypes.